摘要
微小RNA(miRNA)是一类重要调控因子,在转录后水平调控细胞增殖分化、凋亡、分裂以及器官的发育。据估计,miRNA调节着人类细胞大约1/3的蛋白质表达,进而参与几乎所有生命体的生理及病理过程。大量研究证实,内皮特异miRNA参与调控血管新生过程各个环节,在血管新生的调控方面发挥着非常关键的作用。miR-126、miR-210、miR-424、Let-7等具有促进血管新生作用;miR-221/miR-222、miR-34a、miR-217等则具有抑制血管新生作用。并且miRNA合成过程中两个关键性酶Dicer和Drosha也在血管新生中占居重要地位。因此,miRNA可能成为一种新的心血管疾病诊断和靶向治疗的生物学标志物。
MicroRNA（miRNA） is a kind of important regulatory faetws, which contruls the post tran- scriptional regulation of cell ptliferation and differentiation, apoptusis, splitting and organ development. According to the estimation, miRNAs regulate about 1/3 ptein expression of human cells, and they are inw）lved in almost all the physiological and pathological prucesscs. Accumulating evidence indicates that various aspects of angiogenesis can be regulated by specific miRNAs in an endothelial-specific manner. miR-126, miR-210, miR-24, l,ct-7 are pro-angiogenie miRNAs ; miR-221/miR-222, miR-34a, miR-217 are anti-angiogenic miRNAs. Dic.er and Drnsha-the two major enzymes in the processing of miRNA generatiun- have an important role in regulation of endothelial function and angiogenesis as we//. So, as novel molecular targets,miRNAs have a potential value for diagnosis and atment of angiogenesis-assoeiatcd diseases.
出处
《医学综述》
2013年第20期3664-3666,共3页
Medical Recapitulate
基金
上海市自然科学基金(12ZR1417400)
